NovaQuest Capital Management, located in North Carolina’s Research Triangle, is a life science investment firm with a specialization in biopharmaceuticals. Founded in 2010, and with more than $2.5 billion raised across multiple asset classes, NovaQuest provides tailored capital solutions that fund innovation in biopharmaceutical development and invests in compelling healthcare companies with products and technologies aimed at helping humans and animals live healthier, longer, more productive lives.

One Health

Human, animal, and environmental health are inextricably linked. NovaQuest believes the lives of all species, and the environment can be enhanced with a One Health approach to life sciences. Click the image below to learn more about One Health.

Our Timeline

NovaQuest Capital Management has a long and proven history of life sciences investing.

2000
2001-2009
2010
2011
2015
2016
2019
2020

NovaQuest Beginnings

NovaQuest forms as a strategic investment arm within Quintiles Transnational (now IQVIA), laying the foundation for the firm’s product finance and private equity strategies

Investing at Quintiles Transnational

NovaQuest invests over $1 billion across life sciences, pharmaceutical services, and technology

An Independent Firm

NovaQuest Capital becomes an independent firm, spinning out from Quintiles Transnational (IQVIA) to continue its investment strategy

Product Finance Fund III

NovaQuest Capital raises its first institutional fund with approximately $500 million in capital

Product Finance Fund IV

NovaQuest Capital raises approximately $900 million in capital

Platform Expansion

NovaQuest Capital formalizes separate Private Equity strategy and expands the investment team

Product Finance Fund V & Private Equity Fund I

NovaQuest Capital raises approximately $1.2 billion for Product Finance Fund V and $275 million for Private Equity Fund I

Animal Health Expansion

NovaQuest expands its strategy to bring much needed capital in the animal health industry by closing its first animal health transactions.

Our Strategies

Biopharma

Late-stage PRODUCT FINANCE™ investments in global biopharmaceutical products

Learn more

Animal Health

Partnerships with Animal Health Companies

Learn more

NovaQuest in the News

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

11.7.22

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest Capital Management to support continued development of the company’s antibody-cleaving enzyme technology platform across multiple therapeutic areas while extending the expected cash runway through 2024

7.18.22

TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry

5.25.22

View All News

About NovaQuest